These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15337407)

  • 1. Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness.
    Schmid C; Nkunku S; Merolle A; Vounatsou P; Burri C
    Lancet; 2004 Aug 28-Sep 3; 364(9436):789-90. PubMed ID: 15337407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial.
    Burri C; Nkunku S; Merolle A; Smith T; Blum J; Brun R
    Lancet; 2000 Apr; 355(9213):1419-25. PubMed ID: 10791526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness.
    Bisser S; N'Siesi FX; Lejon V; Preux PM; Van Nieuwenhove S; Miaka Mia Bilenge C; Būscher P
    J Infect Dis; 2007 Feb; 195(3):322-9. PubMed ID: 17205469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An alternative form of melarsoprol in sleeping sickness.
    Kennedy PG
    Trends Parasitol; 2012 Aug; 28(8):307-10. PubMed ID: 22704910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled trial of three regimens of melarsoprol in the treatment of Trypanosoma brucei gambiense trypanosomiasis.
    Pépin J; Mpia B
    Trans R Soc Trop Med Hyg; 2006 May; 100(5):437-41. PubMed ID: 16483622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Médecins Sans Frontières programmes.
    Balasegaram M; Young H; Chappuis F; Priotto G; Raguenaud ME; Checchi F
    Trans R Soc Trop Med Hyg; 2009 Mar; 103(3):280-90. PubMed ID: 18947846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The phenomenon of treatment failures in Human African Trypanosomiasis.
    Brun R; Schumacher R; Schmid C; Kunz C; Burri C
    Trop Med Int Health; 2001 Nov; 6(11):906-14. PubMed ID: 11703845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation of Trypanosoma brucei gambiense from cured and relapsed sleeping sickness patients and adaptation to laboratory mice.
    Pyana PP; Ngay Lukusa I; Mumba Ngoyi D; Van Reet N; Kaiser M; Karhemere Bin Shamamba S; Büscher P
    PLoS Negl Trop Dis; 2011 Apr; 5(4):e1025. PubMed ID: 21526217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical presentation and treatment outcome of sleeping sickness in Sudanese pre-school children.
    Eperon G; Schmid C; Loutan L; Chappuis F
    Acta Trop; 2007 Jan; 101(1):31-9. PubMed ID: 17207760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative application of melarsoprol for treatment of T. B. gambiense sleeping sickness. Preliminary results.
    Burri C; Blum J; Brun R
    Ann Soc Belg Med Trop; 1995 Mar; 75(1):65-71. PubMed ID: 7794064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment.
    Burri C; Keiser J
    Trop Med Int Health; 2001 May; 6(5):412-20. PubMed ID: 11348536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of late stage sleeping sickness caused by T.b. gambiense: a new approach to the use of an old drug.
    Blum J; Burri C
    Swiss Med Wkly; 2002 Feb; 132(5-6):51-6. PubMed ID: 11971197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melarsoprol sensitivity profile of Trypanosoma brucei gambiense isolates from cured and relapsed sleeping sickness patients from the Democratic Republic of the Congo.
    Pyana Pati P; Van Reet N; Mumba Ngoyi D; Ngay Lukusa I; Karhemere Bin Shamamba S; Büscher P
    PLoS Negl Trop Dis; 2014 Oct; 8(10):e3212. PubMed ID: 25275572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo.
    Balasegaram M; Harris S; Checchi F; Ghorashian S; Hamel C; Karunakara U
    Bull World Health Organ; 2006 Oct; 84(10):783-91. PubMed ID: 17128358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A seven days course of eflornithine for relapsing Trypanosoma brucei gambiense sleeping sickness.
    Khonde N; Pépin J; Mpia B
    Trans R Soc Trop Med Hyg; 1997; 91(2):212-3. PubMed ID: 9196773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: A critical appraisal of 23 years of experience in the Democratic Republic of Congo.
    Kazumba LM; Kaka JT; Ngoyi DM; Tshala-Katumbay D
    PLoS Negl Trop Dis; 2018 Jun; 12(6):e0006504. PubMed ID: 29897919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of the 10-day melarsoprol schedule for the treatment of second stage Rhodesiense sleeping sickness.
    Kuepfer I; Schmid C; Allan M; Edielu A; Haary EP; Kakembo A; Kibona S; Blum J; Burri C
    PLoS Negl Trop Dis; 2012 Aug; 6(8):e1695. PubMed ID: 22970329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trypanosomiasis relapse after melarsoprol therapy, Democratic Republic of Congo, 1982-2001.
    Pépin J; Mpia B
    Emerg Infect Dis; 2005 Jun; 11(6):921-7. PubMed ID: 15963288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotypic and phenotypic characterization of Trypanosoma brucei gambiense isolates from Ibba, South Sudan, an area of high melarsoprol treatment failure rate.
    Maina N; Maina KJ; Mäser P; Brun R
    Acta Trop; 2007; 104(2-3):84-90. PubMed ID: 17765860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II).
    Schmid C; Richer M; Bilenge CM; Josenando T; Chappuis F; Manthelot CR; Nangouma A; Doua F; Asumu PN; Simarro PP; Burri C
    J Infect Dis; 2005 Jun; 191(11):1922-31. PubMed ID: 15871127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.